$FUL

Head to Head Analysis: H.B. Fuller (NYSE:FUL) vs. AdvanSix (NYSE:ASIX)

The article compares H. B. Fuller (NYSE:FUL) and AdvanSix (NYSE:ASIX) across dividends, valuation, earnings, risk, and ownership. FUL’s dividend is $0.98/share (1.7% yield) vs ASIX’s $0.64 (2.9%); FUL pays 32.3% of earnings vs ASIX 173%. FUL has beta 0.95 vs 1.33, and a $65.50 consensus price target vs $22.50.

Original reporting
Published May 24, 2026, 5:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 24, 2026, 5:52 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Head to Head Analysis: H.B. Fuller (NYSE:FUL) vs. AdvanSix (NYSE:ASIX) — source image
Decision brief

The 30-second read

$FULBullishLow
01

Why it matters

Traders may use it for relative-value rotation between FUL and ASIX, but it lacks a discrete catalyst (earnings, guidance, M&A, litigation, or regulatory action).

02

Market read

Relative attractiveness tilts toward FUL based on dividend sustainability metrics and higher stated analyst upside; ASIX is flagged for higher volatility and dividend coverage risk.

03

What to watch

The comparison omits balance-sheet leverage, cash flow coverage, segment margin trends, and near-term demand/price assumptions that typically drive specialty-chemicals trading.

Relevance 4/10Timing: No event date (earnings/deal/regulatory) is provided; impact is limited to positioning/relative-value screens.

Background

This is a comparative investment-style article (dividends, valuation, risk, ownership, analyst targets) rather than a report of new corporate events.

Company-level read

Ticker impact

$FULBullishMedium confidence
Context

The article compares FUL’s dividend yield, payout ratio, valuation, and analyst upside versus ASIX, implying relative attractiveness for trading.

Expected impact

Near-term bias toward FUL as the “more favorable” name, but magnitude likely limited since no new company-specific catalyst is cited.

Evidence & confidence

The piece is a head-to-head comparison using valuation/dividend/ownership snapshots rather than reporting new events like earnings, guidance, deals, or regulatory actions.

$ASIXBearishMedium confidence
Context

The article highlights ASIX’s higher beta, lower dividend sustainability (payout >100% of earnings), and minimal analyst upside versus FUL.

Expected impact

Potential underperformance bias versus FUL if traders treat the comparison as a signal, though without a fresh catalyst the effect should be modest.

Evidence & confidence

The article provides comparative metrics (dividend payout, beta, price targets) but does not describe new operational or financial developments.

Market effects

Read-across is limited: both are specialty chemicals/basic materials, but the article does not cite sector-wide shocks or policy changes.

None indicated; both companies are discussed as US-listed peers without geographic demand/regulatory catalysts.

None indicated; no global commodity/input price moves or international contract news is referenced.

Counterpoint

ASIX’s dividend payout >100% could reflect timing/one-offs or cyclical earnings; without fundamentals updates, the “unsustainable” conclusion may be overstated.

Key entities

  • H. B. Fuller

    Specialty adhesives and coatings company discussed as the stronger relative pick in the comparison.

  • AdvanSix

    Polymer resins and chemicals company discussed as weaker on dividend coverage and analyst upside.

Related articles

$FULMedAI 8/10

H.B. Fuller board rejects unsolicited bid

H.B. Fuller's board rejected an unsolicited bid for its BAS segment, citing a valuation below market precedent and lack of financing details. The board highlighted BAS's 6% organic growth and 10% EBITDA improvement, noting its importance for future earnings. The board also cited operational integration challenges and reaffirmed its strategic priorities, including the Advanced Medical Solutions acquisition and Project Quantum Leap.

$FULMedAI 8/10

H.B. Fuller stock flat as board rejects Ancora’s adhesives bid

H.B. Fuller Co. (NYSE:FUL) shares were unchanged in premarket trading after its board rejected Ancora Holdings Group's $1.2 billion bid for its building adhesives unit, citing undervaluation and lack of growth potential consideration. Ancora criticized the rejection as irrational and emphasized its ability to finance a higher offer. The bid aimed to help H.B. Fuller reduce debt and focus on integrating Advanced Medical Solutions Group Plc.

$ASIXMed

AdvanSix (ASIX) Offsets Rising Costs With Pricing As Fertilizer Demand Softens

AdvanSix (NYSE:ASIX) reported Q2 sales of $421 million, up about 3% y/y, but adjusted EBITDA fell $24 million to $32 million and adjusted EPS dropped to $0.19. The company said $72 million higher raw material costs were offset by pricing, while fertilizer demand softened, driving unfavorable volume impacts. Guidance includes ammonia volume growth plans for 2026.

$FULMed

AMS shareholders approve H.B. Fuller acquisition proposal

H.B. Fuller (NYSE:FUL) said Advanced Medical Solutions Group plc (LSE:AMS) shareholders approved the proposed cash acquisition of AMS. The approval is a milestone toward closing, which H.B. Fuller expects by year end, subject to remaining conditions and regulatory approvals. H.B. Fuller reported 2025 revenue of $3.5B.

$FULMed

Ancora offers up to $1.2bn for an H.B. Fuller business

Activist investor Ancora Holdings proposes an all-cash offer of up to $1.2bn to buy H.B. Fuller’s Building Adhesive Solutions unit, urging divestiture and offering to start due diligence. Ancora, holding over 2% of shares, says it has received no substantive response and may seek board control via a proxy fight. H.B. Fuller shares were down 2.3% intraday.